Inflammatory F2-isoprostane, prostaglandin F2α, pentraxin 3 levels and breast cancer risk: The Swedish Mammography Cohort
详细信息 查看全文
- 作者：Samar Basua ; b ; ; Holly Harrisc ; d ; e ; Alicja Wolkc ; Adrien Rossarya ; Florence Caldefie-Ché ; zeta ; Marie-Paule Vassona ; f ; g ; Anders Larssonh
- 关键词：ADME ; absorption ; distribution ; metabolism and excretion ; BBD ; benign breast disease ; BMI ; body-mass index ; CRP ; C-reactive proteins ; CV ; coefficient of variation ; CI ; confidence interval ; DNA ; deoxyribonucleic acid ; 8-iso-PGF2α ; 8-iso-prostaglandin F2α ; OR ; odds ratio ; PGE-M ; prostaglandin E metabolite ; PGF2α ; prostaglandin F2α ; PTX3 ; pentraxin 3 ; SMC ; Swedish Mammography Cohort
- 刊名：Prostaglandins, Leukotrienes and Essential Fatty Acids
- 出版年：2016
- 出版时间：October 2016
- 年：2016
- 卷：113
- 期：Complete
- 页码：28-32
- 全文大小：271 K
文摘
- •
Breast cancer is a life-threatening and leading cause of cancer death among women.
- •
Recognizing cellular participation we hence examined if prediagnostic circulating levels of F2-isoprostane, PGF2α and PTX3 were associated with breast cancer risk.
- •
Assessing systemic levels of these biomarkers early to define breast cancer risk is most relevant.
- •
None of these examined biomarkers were significantly associated with breast cancer risk.
- •
These findings reveal a new understanding on the role of systemic F2-isoprostane, PGF2α and PTX3 in breast cancer which provide no prognostic information on tumor development in spite of their known involvement in situ cellular context.